各位股东及股东代表： 本人作为雅本化学股份有限公司（以下简称"公司"）的独立董事，在任职 期间严格按照《公司法》《证券法》《上市公司独立董事规则》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—— 创业板上市公司规范运作》《公司章程》《独立董事制度》等相关法律法规， 诚实、勤勉、独立的履行职责，积极出席相关会议，认真审议董事会各项议案， 对公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会的作用， 努力维护公司股东，特别是中小股东的合法权益。现将2023年度本人的工作情 况报告如下： 一、 独立董事基本情况及独立性自查情况 严嘉，男，1971年生，博士研究生。曾任美国宝维斯律师事务所律师，香港 中华法律集团运营总监。现任美国普衡律师事务所律师、合伙人，益方生物科 技（上海）股份有限公司独立董事，雅本化学股份有限公司独立董事，上海飞 乐音响股份有限公司独立董事。 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在妨碍 本人进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上 ...

Financial Performance - The company's revenue for Q1 2024 was ¥219,942,064.63, a decrease of 54.06% compared to ¥478,738,677.64 in the same period last year[5] - The net loss attributable to shareholders was ¥45,576,667.50, representing a decline of 185.65% from a profit of ¥53,215,317.80 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0475, a decrease of 185.28% from ¥0.0557 in the same period last year[5] - The net profit for the first quarter of 2024 was -44,286,323.71 CNY, compared to a net profit of 52,294,452.98 CNY in the same period last year, representing a significant decline[20] - The company reported a total comprehensive income of -57,137,857.45 CNY for the first quarter, compared to 57,873,413.39 CNY in the same quarter last year[21] Cash Flow and Liquidity - The net cash flow from operating activities was ¥6,343,271.16, down 94.09% from ¥107,265,279.07 in Q1 2023[5] - The cash and cash equivalents at the end of the period were 314,720,829.76 CNY, down from 451,657,264.02 CNY at the end of the previous year, a decrease of approximately 30.3%[24] - The company incurred a loss of -50,531,001.17 CNY in operating profit, contrasting with an operating profit of 61,431,600.21 CNY in the same quarter last year[20] - The company's investment activities resulted in a net cash outflow of -34,739,365.09 CNY, compared to -59,915,264.87 CNY in the previous year, showing an improvement in cash flow management[24] - The financing activities generated a net cash inflow of 117,285,445.73 CNY, significantly higher than 25,835,029.21 CNY in the same period last year, indicating increased financing efforts[24] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥4,192,018,181.26, an increase of 1.13% from ¥4,145,222,725.41 at the end of the previous year[5] - Total liabilities increased to CNY 1,777,396,469.51 from CNY 1,717,475,770.19, marking a rise of 3.5%[18] - The company's equity attributable to shareholders decreased to CNY 2,258,389,004.97 from CNY 2,274,817,267.89, a decline of 0.7%[18] Research and Development - The company's R&D expenses decreased by 30.36% to ¥19,379,345.49 from ¥27,826,005.82 in Q1 2023[9] - Research and development expenses for Q1 2024 were CNY 19,379,345.49, down 30.4% from CNY 27,826,005.82 in the previous year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 80,029[11] - Ningbo Yabao Holdings holds 26.75% of shares, totaling 257,729,839 shares[11] - The company has a new employee stock ownership plan for 2023, holding 8,623,900 shares[11] - The company has 6.75% of shares held by foreign individual shareholder Wang Xinya, totaling 65,000,350 shares[11] - The company has 2.91% of shares held by Zhang Yuxin, totaling 28,010,000 shares[11] - The company has 2.53% of shares held by Cai Tong, totaling 24,376,051 shares, with 18,282,038 shares under pledge[11] - The company has 0.73% of shares held by Jin Xiangguo and Liao Guopei, each totaling 7,000,000 shares[11] Legal Matters - The company has 43 ongoing lawsuits with a total amount involved of 2,593,035,000 CNY, which will not significantly impact financial statements[13] - The company has paid 2,383,525.20 CNY in relation to a judgment that has come into effect[13] Investment Income - The company reported a significant decrease in investment income, down 50.03% to ¥941,210.32 from ¥1,883,366.72 in the same period last year[9] - The company reported an investment income of CNY 941,210.32, a decrease of 50.0% compared to CNY 1,883,366.72 in the same period last year[19] Fair Value Changes - The company experienced a 240.07% decline in fair value changes, reporting a loss of ¥6,655,670.00 compared to a gain of ¥4,751,745.00 in the previous year[9] Accounts Receivable and Inventory - Accounts receivable decreased to CNY 511,030,145.46 from CNY 573,663,679.59, a decline of 10.9%[16] - Inventory increased to CNY 614,976,811.90 from CNY 587,282,262.37, reflecting a rise of 4.7%[16]

雅本化学。 出生 J 环境、社会及治理(ESG)报告 2023年度 版 编制造 ABA CHEM D 联系电话:021-51159199 邮箱: boardoffice@abachem.com 网址: https://www.abachem.com C 地址：上海市普陀区中江路118弄22号海亮大厦A座15层 雅本化学股份有限公司 关于本报告 本报告是雅本化学股份有限公司携旗下成员企业正式发布的第一份年度环境、社会及治理报告（以下简 称"本报告"），旨在阐述公司在"环境、社会及治理"（以下简称"ESG"）方面的制度建设与经营活 动表现，客观披露公司在可持续发展方面的管理和成效，以响应利益相关方与社会公众的期望。 报告范围 本报告覆盖雅本化学股份有限公司及其下属公 司。为便于表述与方便阅读，在本报告中"雅本 化学股份有限公司"简称"雅本化学"、"公 司"或"我们" 等。下属公司涵盖：上海雅本化 学有限公司、南通雅本化学有限公司、雅本（绍 兴)药业有限公司、江苏建农植物保护有限公 司、甘肃兰沃科技有限公司、兰州雅本精细化工 有限公司、上海朴颐化学科技有限公司、湖州颐 辉生物科技有限公司、兰州雅本药物创制科技有 限 ...

雅本化学股份有限公司 独立董事2023年度述职报告 各位股东及股东代表： 本人作为雅本化学股份有限公司（以下简称"公司"）的独立董事，在任职 期间严格按照《公司法》《证券法》《上市公司独立董事规则》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—— 创业板上市公司规范运作》《公司章程》《独立董事制度》等相关法律法规， 诚实、勤勉、独立的履行职责，积极出席相关会议，认真审议董事会各项议案， 对公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会的作用， 努力维护公司股东，特别是中小股东的合法权益。现将2023年度本人的工作情 况报告如下： 一、 独立董事基本情况及独立性自查情况 饶艳超女士，中国国籍，无永久境外居留权，女，汉族，1973年生，博士。 历任南昌大学经济系助教，上海财经大学会计学院讲师，福然德股份有限公司 独立董事，深圳市宇顺电子股份有限公司独立董事，浙江瑞晟智能科技股份有 限公司独立董事。现任上海财经大学副教授，雅本化学股份有限公司独立董事， 上海新诤信知识产权服务股份有限公司独立董事。 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， ...

证券代码： 300261 证券简称： 雅本化学 公告编号： 2024-034 雅本化学股份有限公司 关于2023年度计提资产减值准备和信用减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 雅本化学股份有限公司(以下简称"公司")根据《深圳证券交易所上市公 司自律监管指引第2号——创业板上市公司规范运作》《企业会计准则》以及公 司相关会计政策的规定，计提了信用减值损失及资产减值损失。本次计提资产 减值准备无需提交公司董事会和股东大会审议。现将具体情况公告如下： 一、本次计提资产减值准备和信用减值准备的原因 根据《企业会计准则》《深圳证券交易所上市公司自律监管指引第2号—— 创业板上市公司规范运作》及公司会计政策等相关规定的要求，基于谨慎性原则， 为真实准确地反映公司截至2023年12月31日的财务状况和经营成果，公司对合并 报表范围内截至2023年12月31日的应收账款、其他应收款、存货、合同资产等各 类资产进行了全面清查，对各项资产减值的可能性进行了充分的评估和分析，对 存在减值迹象的资产计提相应减值准备。 二、本次计提信用减值准备及资产减值准备 ...

| | 务规则和公司章程规定的不具备独立性的其他人 | | | --- | --- | --- | | | 员。 | | | 8 | 如上述任何一项填写为"是"，请在以下就具体事宜 | □是（（（（否 | | | 进行详细解释：____________________________ | | 经自查，本人在 2023（年度不存在影响独立性情形。 报告人：严嘉 本人严格遵守《公司法》《上市公司治理准则》和《上市公司独立董事管理 办法》等法律法规以及《公司章程》对独立董事的任职要求，持续保持独立性。 | 序号 | 事项 | 自查结果 | | --- | --- | --- | | 1 | 在上市公司或者其附属企业任职的人员及其配偶、 | □是（（（（否 | | | 父母、子女、主要社会关系； | | | 2 | 直接或者间接持有上市公司已发行股份百分之一以 | □是（（（（否 | | | 上或者是上市公司前十名股东中的自然人股东及其 | | | | 配偶、父母、子女； | | | 3 | 在直接或者间接持有上市公司已发行股份百分之五 | □是（（（（否 | | | 以上的股东或者在上市公司前五名股东任职的 ...

证券代码：300261 证券简称：雅本化学 公告编号：2024-031 雅本化学股份有限公司 关于2023年度不进行利润分配的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 雅本化学股份有限公司（以下简称"公司"）于2023年4月25日召开第五届董事会 第十七次会议和第五届监事会第十六次会议审议通过了《关于2023年度利润分配预 案的议案》，本议案尚需提交公司2023年年度股东大会审议。现将该议案的基本情 况公告如下： 一、2023年度利润分配预案 经大华会计师事务所（特殊普通合伙）为公司出具的标准无保留意见审计报告 确认，2023年度，公司实现营业总收入127,884.83万元，同比下降36.09%；实现归 属于上市公司股东的净利润为-8,229.38万元，同比下降140.55%。 鉴于公司2023年度未盈利，为保证公司能够持续经营和长期发展并更好地维护 全体股东的长远利益，公司拟定2023年度利润分配预案为：拟不派发现金红利、不 送红股、不以资本公积金转增股本。 留存未分配利润将主要用于满足公司日常经营需要，支持公司各项业务的开展以及 流动资金需求等 ...

Financial Performance - The company reported a net profit attributable to shareholders of -82,293,808.08 RMB for the year 2023, indicating a significant decline compared to the previous year[5]. - The decline in revenue and net profit was primarily due to a cyclical downturn in the agricultural chemical industry, customer inventory adjustments, and a notable reduction in orders for pharmaceutical business[5]. - The company's operating revenue for 2023 was ¥1,278,848,252, a decrease of 36.09% compared to ¥2,000,975,899 in 2022[23]. - The net profit attributable to shareholders for 2023 was ¥82,293,808, representing a decline of 140.55% from ¥181,849,264 in 2022[23]. - The net cash flow from operating activities was negative at ¥25,854,785, a decrease of 131.89% compared to ¥81,067,227 in 2022[23]. - The basic and diluted earnings per share for 2023 were both -¥0.0862, down from ¥0.2126 in 2022, marking a decline of 140.55%[23]. - The company reported a quarterly operating revenue of ¥478,738,678 in Q1, which decreased to ¥178,273,401 in Q4[29]. - The net profit attributable to shareholders in Q4 was -¥158,951,772, following positive profits in the first three quarters[29]. Strategic Initiatives - The company emphasizes its commitment to research and development, particularly in the pharmaceutical sector, to enhance its product offerings[5]. - The company continues to focus on its main business areas and is exploring opportunities for market expansion and strategic partnerships[5]. - The company has set a revenue guidance of 1.5 billion yuan for the next fiscal year, representing a 20% growth compared to the previous year[49]. - The company is actively pursuing market expansion, targeting new regions in Asia and Europe, aiming for a 30% increase in market penetration by 2025[49]. - Strategic partnerships with Fortune 500 companies have been established, enhancing supply chain stability and increasing production capacity[49]. - The company plans to enhance its manufacturing capabilities through potential acquisitions, targeting a 15% increase in production efficiency[49]. Research and Development - The company operates four R&D centers focusing on technology and product innovation, optimizing processes, and transforming results[42]. - The company has invested 200 million yuan in R&D for new technologies, aiming to improve product efficacy and reduce environmental impact[49]. - The company's R&D investment has increased from 0.15 million to 1.2 million in 2023, demonstrating a commitment to continuous innovation[57]. - The company is focusing on increasing its market share in the plant growth regulator category, with products like 15% and 25% paclobutrazol showing promising growth potential[51][52]. - Ongoing research and development efforts are directed towards enhancing the effectiveness of existing products and exploring new active ingredients[50]. Environmental Commitment - The company is committed to sustainability, with initiatives aimed at reducing carbon emissions by 25% over the next five years[49]. - The company has established comprehensive wastewater and waste gas treatment facilities to ensure compliance with environmental standards, aiming to minimize negative ecological impacts[182]. - The company reported a total discharge of 3.32213 tons of COD, with a maximum concentration of 133 mg/l, during the reporting period[184]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[182]. - The company has implemented a compliance evaluation process to adapt to new environmental regulations and standards[182]. Corporate Governance - The company held four shareholder meetings in 2023, ensuring equal rights for shareholders and compliance with legal procedures[135]. - The board of directors consists of 9 members, including 3 independent directors, and operates in accordance with legal and regulatory requirements[136]. - The company has established a fair and transparent performance evaluation and incentive mechanism, promoting effective management and employee motivation[139]. - The company actively engages with stakeholders to respect and protect their legitimate rights and interests, fostering balanced development[139]. - The company is committed to maintaining high standards of corporate governance and transparency in its operations[148]. Market Outlook - The global pesticide market is projected to grow at a CAGR of 5.6% from 2023 to 2030, driven by increasing food security concerns and regulatory pressures[38]. - The Chinese chemical raw materials market is expected to reach ¥473.6 billion in revenue by 2023, indicating a recovery trend in the industry[39]. - The company plans to enhance production capacity utilization in 2024, focusing on flexible production and green sustainable development[61]. - The company aims to achieve a comprehensive technology innovation system from small-scale testing to commercial production[58]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic investments and technology development[114].

本人严格遵守《公司法》《上市公司治理准则》和《上市公司独立董事管理 办法》等法律法规以及《公司章程》对独立董事的任职要求，持续保持独立性。 雅本化学股份有限公司 独立董事关于2023年度独立性的自查报告 本人饶艳超，于 2022 年 3 月 1 日起任职雅本化学股份有限公司（ 以下简称"上 市公司"）独立董事，在 2023 年度任职时间为 2023 年 1 月 1 日-2023 年 12 月 31 日。 | | 务规则和公司章程规定的不具备独立性的其他人 | | | --- | --- | --- | | | 员。 | | | 8 | 如上述任何一项填写为"是"，请在以下就具体事宜 | □是（（（（否 | | | 进行详细解释：____________________________ | | 经自查，本人在 2023 年度不存在影响独立性情形。 报告人：饶艳超 二〇二四年四月二十九日 | 本人 | | | --- | --- | | 2023 | 年度独立性自查情况如下： | | 序号 | 事项 | 自查结果 | | --- | --- | --- | | 1 | 在上市公司或者其附属企业任职的人员及其配偶 ...

雅本化学股份有限公司 一、2023年度公司主要经营指标完成情况 2023 年是公司发展进程中充满挑战、艰苦奋斗的一年，面对行业进入周期性调 整及公司终端客户需求减少的多重考验，公司推行蓄力调整、提质增效策略，围绕 创新农药、创新医药等主营业务方向重点发力，通过科学管理、精益生产、高效投 资巩固与重点客户在创新中间体方面的合作，牢固树立 CDMO 行业领先服务商形 象。 2023年度公司实现营业收入127,884.83万元，较上年同期下降36.09%，营业利润 -7,850.95万元，较上年同期下降131.10%；利润总额-8,881.93万元，较上年同期下降 136.33%；实现归属于母公司净利润为-8,229.38万元，比上年同期下降140.55%。 二、2023年度董事会日常工作情况 2023年度，公司董事会全体董事勤勉尽责，认真履行《公司法》《证券法》等 法律法规和《公司章程》赋予的职责，严格执行股东大会各项决议，持续提高公司 治理水平，并将ESG管理要求纳入公司章程和相关管理制度中，不断推进绿色发展， 为公司经营事项的科学决策与各项业务的发展贡献积极的作用。 （一）董事会召开会议的情况 2023年度董 ...